{"preliminary_commentary":{"by_channel":{"youtube":2,"podcast":1,"x_thread":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06521567","nct_id":"NCT06521567","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06521567. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Part 1- Dose determination","type":"EXPERIMENTAL"},{"description":null,"label":"Part 2- Dose expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-10-13","type":"ESTIMATED"},"conditions":["Melanoma","Hodgkin Lymphoma","High and Low Grade Glioma","Glioblastoma Multiforme (GBM)","Diffuse Intrinsic Pontine Glioma (DIPG)","Ependymoma","Osteosarcoma","Hepatic Tumors","Hepatoblastoma","Hepatocellular Carcinoma (HCC)","Fibrolamellar Carcinoma","Rhabdomyosarcoma"],"enrollment":{"count":83,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cobolimab","otherNames":[],"type":"DRUG"},{"name":"Dostarlimab","otherNames":[],"type":"DRUG"}],"last_update":"2025-11-12","lead_sponsor":"GlaxoSmithKline","official_title":"Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-10-13","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1- Number of participants with Dose Limiting Toxicities (DLTs)","timeFrame":"Up to 42 days"},{"measure":"Part 1- Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs) and adverse events (AEs) leading to discontinuation occurring during the study","timeFrame":"Up to approximately 46 months"},{"measure":"Part 1- Serum concentration of Cobolimab","timeFrame":"1±0.5 hours (h) post-dose on Cycle 1 Day 1; 168±12 h post-dose Cycle 1Day 8; Pre-dose and 1±0.5 h post-dose on Cycle 2 Day 1; Cycle 4 Day 1 and Cycle 6 Day 1(Each cycle is of 21 days)"},{"measure":"Part 1- Serum concentration of Dostarlimab","timeFrame":"1±0.5 h post start of cobolimab infusion on Cycle 1 Day 1; Pre-dose on Cycle 2 Day 1; Cycle 4 Day 1 and Cycle 6 Day 1(Each cycle is of 21 days)"},{"measure":"Part 1- Recommended Phase 2 Dose (RP2D) of Cobolimab and Dostarlimab combination","timeFrame":"Up to approximately 12 months"},{"measure":"Part 2- Confirmed Objective Response Rate (ORR)","timeFrame":"Up to approximately 46 months"},{"measure":"Part 2- Number of participants with TEAEs, SAEs, imAEs, TEAEs leading to death and AEs leading to discontinuation","timeFrame":"Up to approximately 46 months"},{"measure":"Part 2-Number of participants with changes in laboratory parameters, vital signs and cardiac parameters","timeFrame":"Up to approximately 46 months"}],"references":[],"start_date":{"date":"2025-03-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer","url":"https://clinicaltrials.gov/study/NCT06521567"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06521567"}